Seeking Alpha

Bristol Myers' (BMY) BMS-936558, which shrank tumors in advanced lung, kidney and skin cancer in...

Bristol Myers' (BMY) BMS-936558, which shrank tumors in advanced lung, kidney and skin cancer in 18%-28% of patients, is at the forefront of treatments designed to enable the body's immune-system to kill cancer cells. Other firms in this "revolution in the making" include Merck (MRK), Roche (RHHBY.PK), Teva (TEVA) and GSK (GSK).
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|